NCT01939353View on ClinicalTrials.gov

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 3, 2013

Primary Completion Date

February 20, 2014

Study Completion Date

February 20, 2014

Conditions

Adult ADHD

Interventions

DRUG

CTN SR

CTN SR tablets

DRUG

Placebo

CTN SR-matching placebo tablets

Trial Locations (3)

32751

Maitland

34201

Bradenton

89128

Las Vegas

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01939353 - Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder | Biotech Hunter | Biotech Hunter